Cardio Flow Funding: How Much Did They Raise & Key Investors

How Much Did Cardio Flow Raise?
Funding & Key Investors

Cardio Flow has successfully secured a significant capital injection, bringing its total funding to $4.3M. This latest financing round, which accounts for $4.3M, underscores the market confidence in the company's specialized approach to vascular intervention. By securing this major strategic investment, the firm is well-positioned to accelerate the commercialization of its proprietary medical technologies within the competitive cardiovascular landscape.

The infusion of capital serves as a critical milestone for the organization, enabling the scaling of operations and the expansion of its clinical footprint. As the medical device sector continues to prioritize cost-effective and efficient treatment modalities, Cardio Flow remains at the forefront of addressing the growing prevalence of complex vascular conditions through its innovative engineering.

What is Cardio Flow?

Cardio Flow

Manufacturing

Medical Devices & Equipment

Cardio Flow, Inc. is a medical technology innovator dedicated to the development of the FreedomFlow Orbital Atherectomy Platform. The company focuses on providing physicians with a versatile and efficient solution for treating Peripheral Artery Disease (PAD). By utilizing a unique mechanism of action, the platform is engineered to accommodate a wide range of vessel diameters, thereby optimizing clinical workflows and reducing the economic burden on healthcare facilities. The company's core mission is to empower healthcare providers to treat multiple lesions and blockages effectively, ultimately aiming to reduce the incidence of PAD-related amputations through advanced, minimally invasive technology.

How much funding has Cardio Flow raised?

Cardio Flow has raised a total of $4.3M across 1 funding round:

2019

Unspecified

$4.3M

Unspecified (2019): $4.3M, investors not publicly disclosed

Key Investors in Cardio Flow

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Cardio Flow?

With the recent influx of capital, Cardio Flow is poised to transition into a more aggressive growth phase, focusing on the widespread adoption of the FreedomFlow platform. The strategic roadmap likely includes expanding clinical trials to demonstrate long-term efficacy, enhancing manufacturing capabilities to meet anticipated demand, and strengthening market penetration in both hospital and outpatient clinic settings. By leveraging this financial backing, the company is set to refine its technological edge, ensuring that its orbital atherectomy solutions remain the standard for complex PAD management. Future efforts will likely center on scaling the sales infrastructure and fostering partnerships with key opinion leaders in the vascular surgery community to solidify its market position.

See full Cardio Flow company page

See More Financial Insights